Investment Firm, Stanford Form Private Health Research Company

<p><a href&equals;"https&colon;&sol;&sol;www&period;stanford&period;edu&sol;">Stanford University<&sol;a> is teaming up with <a href&equals;"https&colon;&sol;&sol;deerfield&period;com&sol;">Deerfield Management<&sol;a>&comma; a New York-based health care investment firm&comma; to create Porter Alliance for Innovative Medicines that will accelerate translational research into clinical therapeutics&period;<&sol;p>&NewLine;<p>Deerfield has committed up to &dollar;130 million and additional scientific and operational support to this new collaboration to advance research coming out of Stanford faculty laboratories with a focus on drug prototypes emerging from Stanford’s <a href&equals;"https&colon;&sol;&sol;ima&period;stanford&period;edu&sol;">Innovative Medicines Accelerator<&sol;a>&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The Porter Alliance for Innovative Medicines aims to close a historic gap between scientific research and clinical care&comma;” said <a href&equals;"https&colon;&sol;&sol;med&period;stanford&period;edu&sol;profiles&sol;lloyd-minor">Lloyd Minor<&sol;a>&comma; MD&comma; dean of the <a href&equals;"https&colon;&sol;&sol;med&period;stanford&period;edu&sol;">Stanford University School of Medicine<&sol;a>&period; &OpenCurlyDoubleQuote;This collaboration with Deerfield Management will ensure that Stanford’s breakthroughs in biomedical research translate rapidly to treatments and cures for patients&period;”<&sol;p>&NewLine;<p>The newly launched Porter Alliance for Innovative Medicines is a private company that will be wholly owned by affiliates of Deerfield Management&period; Its objective is to fund projects that have uncovered novel therapeutics that have the potential to cure life-altering diseases&period; This collaboration will rely on the robust and diverse drug pipeline already established by Stanford’s Innovative Medicines Accelerator&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are proud to collaborate with Stanford University to help build the bridge that connects basic research to patient cures&comma;” said James Flynn&comma; managing partner at Deerfield Management&period; &OpenCurlyDoubleQuote;It requires tremendous infrastructure and support to change the probability of success and speed to market for discovery&period; Through Porter Alliance&comma; Stanford investigators will receive the necessary resources&comma; expertise and management to advance their outstanding science&period;”<&sol;p>&NewLine;<p>The collaboration will be governed by a joint steering committee comprising equal representation from Deerfield and Stanford University&period; Stanford researchers will be encouraged to submit proposals for consideration for execution through the collaboration&period;  Accepted proposals will receive a development plan aimed at achieving investigational new drug readiness&period; Selected proposals will also have the eligibility for additional capital investments to create spin-off companies&period;<&sol;p>&NewLine;<p>The Porter Alliance connects Stanford to the broader biopharmaceutical industry and helps researchers understand the problems they need to solve to make transformative medicines&period; A key partner in the collaboration is the Innovative Medicines Accelerator&comma; established as part of Stanford’s vision to be a more purposeful university by turning breakthrough discoveries into solutions for the world&&num;8217&semi;s most pressing problems&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;The Innovative Medicines Accelerator is helping Stanford faculty transform their discoveries into prototype medicines&comma; and we must do whatever we can to ensure those medicines get to the patients who need them&comma;” said <a href&equals;"https&colon;&sol;&sol;profiles&period;stanford&period;edu&sol;chaitan-khosla">Chaitan Khosla<&sol;a>&comma; PhD&comma; director of the Innovative Medicines Accelerator and professor of chemistry and of chemical engineering at Stanford University&period; &OpenCurlyDoubleQuote;I am excited and grateful that the Porter Alliance for Innovative Medicines will serve as a bridge between our promising prototypes and approved therapeutics&period;”<&sol;p>&NewLine;

Editor

Transcripta Bio Lands $24 Million Series A

PALO ALTO -- Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular…

1 day

Whale Bags $40 Million Series C Extension

SAN FRANCISCO -- Whale, a Singapore-based enterprise AI company, has secured a $40 million Series…

1 day

Anthropic to Deploy 2 Gigawatts of AMD GPUs

SANTA CLARA -- AMD and Anthropic have announced a strategic partnership to deploy up to…

1 day

Jensen Huang Visits Naval Postgraduate School

NVIDIA founder and CEO Jensen Huang visited the Naval Postgraduate School in Monterey, CA, this…

1 day

Spectro Cloud Scores $100 Million Series D

SAN JOSE — Spectro Cloud, a provider of AI infrastructure management software, has raised more…

6 days

One Carmel Launches Sales for 73 Estate Homes

CARMEL VALLEY, CA -- ONE Carmel, a private residential community spanning 891 acres in Carmel Valley, California,…

6 days